198 related articles for article (PubMed ID: 33579439)
1. Tailoring functional nanostructured lipid carriers for glioblastoma treatment with enhanced permeability through in-vitro 3D BBB/BBTB models.
Zwain T; Alder JE; Sabagh B; Shaw A; Burrow AJ; Singh KK
Mater Sci Eng C Mater Biol Appl; 2021 Feb; 121():111774. PubMed ID: 33579439
[TBL] [Abstract][Full Text] [Related]
2. Overcoming biological barriers BBB/BBTB by designing PUFA functionalised lipid-based nanocarriers for glioblastoma targeted therapy.
Zwain T; Alder JE; Zwayen S; Shaw A; Burrow AJ; Singh KK
Biomater Adv; 2023 Dec; 155():213660. PubMed ID: 37976832
[TBL] [Abstract][Full Text] [Related]
3. Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers.
Farshbaf M; Mojarad-Jabali S; Hemmati S; Khosroushahi AY; Motasadizadeh H; Zarebkohan A; Valizadeh H
J Control Release; 2022 May; 345():371-384. PubMed ID: 35301054
[TBL] [Abstract][Full Text] [Related]
4. RIPL peptide-conjugated nanostructured lipid carriers for enhanced intracellular drug delivery to hepsin-expressing cancer cells.
Lee SG; Kim CH; Sung SW; Lee ES; Goh MS; Yoon HY; Kang MJ; Lee S; Choi YW
Int J Nanomedicine; 2018; 13():3263-3278. PubMed ID: 29910614
[TBL] [Abstract][Full Text] [Related]
5. Nanostructured lipid carriers, solid lipid nanoparticles, and polymeric nanoparticles: which kind of drug delivery system is better for glioblastoma chemotherapy?
Qu J; Zhang L; Chen Z; Mao G; Gao Z; Lai X; Zhu X; Zhu J
Drug Deliv; 2016 Nov; 23(9):3408-3416. PubMed ID: 27181462
[TBL] [Abstract][Full Text] [Related]
6. Cysteine-Functionalized Nanostructured Lipid Carriers for Oral Delivery of Docetaxel: A Permeability and Pharmacokinetic Study.
Fang G; Tang B; Chao Y; Xu H; Gou J; Zhang Y; Xu H; Tang X
Mol Pharm; 2015 Jul; 12(7):2384-95. PubMed ID: 25974386
[TBL] [Abstract][Full Text] [Related]
7. Core-matched encapsulation of an oleate prodrug into nanostructured lipid carriers with high drug loading capability to facilitate the oral delivery of docetaxel.
Sun B; Luo C; Li L; Wang M; Du Y; Di D; Zhang D; Ren G; Pan X; Fu Q; Sun J; He Z
Colloids Surf B Biointerfaces; 2016 Jul; 143():47-55. PubMed ID: 27011346
[TBL] [Abstract][Full Text] [Related]
8. Enhanced docetaxel delivery using sterically stabilized RIPL peptide-conjugated nanostructured lipid carriers: In vitro and in vivo antitumor efficacy against SKOV3 ovarian cancer cells.
Kim CH; Kang TH; Kim BD; Lee TH; Yoon HY; Goo YT; Choi YS; Kang MJ; Choi YW
Int J Pharm; 2020 Jun; 583():119393. PubMed ID: 32376445
[TBL] [Abstract][Full Text] [Related]
9. Nanostructured lipid carriers loaded with simvastatin: effect of PEG/glycerides on characterization, stability, cellular uptake efficiency and in vitro cytotoxicity.
Safwat S; Ishak RAH; Hathout RM; Mortada ND
Drug Dev Ind Pharm; 2017 Jul; 43(7):1112-1125. PubMed ID: 28276784
[TBL] [Abstract][Full Text] [Related]
10. SN38 loaded nanostructured lipid carriers (NLCs); preparation and in vitro evaluations against glioblastoma.
Shirazi AS; Varshochian R; Rezaei M; Ardakani YH; Dinarvand R
J Mater Sci Mater Med; 2021 Jun; 32(7):78. PubMed ID: 34191134
[TBL] [Abstract][Full Text] [Related]
11. Indinavir-Loaded Nanostructured Lipid Carriers to Brain Drug Delivery: Optimization, Characterization and Neuropharmacokinetic Evaluation.
Nasiri M; Azadi A; Zanjani MRS; Hamidi M
Curr Drug Deliv; 2019; 16(4):341-354. PubMed ID: 30674257
[TBL] [Abstract][Full Text] [Related]
12. Glioblastoma multiforme targeted delivery of docetaxel using bevacizumab-modified nanostructured lipid carriers impair in vitro cell growth and in vivo tumor progression.
Di Filippo LD; Lobato Duarte J; Hofstätter Azambuja J; Isler Mancuso R; Tavares Luiz M; Hugo Sousa Araújo V; Delbone Figueiredo I; Barretto-de-Souza L; Miguel Sábio R; Sasso-Cerri E; Martins Baviera A; Crestani CC; Teresinha Ollala Saad S; Chorilli M
Int J Pharm; 2022 Apr; 618():121682. PubMed ID: 35307470
[TBL] [Abstract][Full Text] [Related]
13. pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation.
Kim CH; Sa CK; Goh MS; Lee ES; Kang TH; Yoon HY; Battogtokh G; Ko YT; Choi YW
Int J Nanomedicine; 2018; 13():6661-6675. PubMed ID: 30425481
[TBL] [Abstract][Full Text] [Related]
14. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
Song S; Mao G; Du J; Zhu X
Drug Deliv; 2016 May; 23(4):1404-8. PubMed ID: 26203687
[TBL] [Abstract][Full Text] [Related]
15. Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema.
Gao S; Tian B; Han J; Zhang J; Shi Y; Lv Q; Li K
Int J Nanomedicine; 2019; 14():6135-6150. PubMed ID: 31447556
[No Abstract] [Full Text] [Related]
16. Size-exclusive effect of nanostructured lipid carriers on oral drug delivery.
Li H; Chen M; Su Z; Sun M; Ping Q
Int J Pharm; 2016 Sep; 511(1):524-537. PubMed ID: 27452421
[TBL] [Abstract][Full Text] [Related]
17. Nanostructured lipid carriers with exceptional gastrointestinal stability and inhibition of P-gp efflux for improved oral delivery of tilmicosin.
Zhang Q; Yang H; Sahito B; Li X; Peng L; Gao X; Ji H; Wang L; Jiang S; Guo D
Colloids Surf B Biointerfaces; 2020 Mar; 187():110649. PubMed ID: 31767412
[TBL] [Abstract][Full Text] [Related]
18. Enhanced blood brain barrier permeability and glioblastoma cell targeting via thermoresponsive lipid nanoparticles.
Rehman M; Madni A; Shi D; Ihsan A; Tahir N; Chang KR; Javed I; Webster TJ
Nanoscale; 2017 Oct; 9(40):15434-15440. PubMed ID: 28976512
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/brain tumor barriers for glioblastoma treatment.
Wang D; Wang C; Wang L; Chen Y
Drug Deliv; 2019 Dec; 26(1):551-565. PubMed ID: 31928355
[TBL] [Abstract][Full Text] [Related]
20. Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables.
Rathod VR; Shah DA; Dave RH
Drug Dev Ind Pharm; 2020 Mar; 46(3):443-455. PubMed ID: 32037896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
